Screener
Novavax NVAX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current portion of finance lease liabilities | 4,110 | 2,507 |
| Other current liabilities | 135,527 | 137,778 |
| Liabilities held for sale | — | 47,869 |
| Total current liabilities | 330,574 | 459,950 |
| Deferred revenue | 356,755 | 358,943 |
| Long-term debt | 291,490 | 244,213 |
| Non-current finance lease liabilities | 1,719 | 2,091 |
| Other non-current liabilities | 165,744 | 239,068 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's total current liabilities?
- Novavax (NVAX) reported total current liabilities of $330.57M in Q2 2026.
- How has Novavax's total current liabilities changed year-over-year?
- Novavax's total current liabilities decreased by 15.0% year-over-year, from $389.14M to $330.57M.
- What is the long-term trend for Novavax's total current liabilities?
- Over 5 years (2020 to 2025), Novavax's total current liabilities has grown at a -4.5% compound annual growth rate (CAGR), from $579.67M to $459.95M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Novavax's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude